These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 15613695)

  • 1. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab.
    Horning SJ; Younes A; Jain V; Kroll S; Lucas J; Podoloff D; Goris M
    J Clin Oncol; 2005 Feb; 23(4):712-9. PubMed ID: 15613695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma.
    Leahy MF; Seymour JF; Hicks RJ; Turner JH
    J Clin Oncol; 2006 Sep; 24(27):4418-25. PubMed ID: 16940276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma.
    Davies AJ; Rohatiner AZ; Howell S; Britton KE; Owens SE; Micallef IN; Deakin DP; Carrington BM; Lawrance JA; Vinnicombe S; Mather SJ; Clayton J; Foley R; Jan H; Kroll S; Harris M; Amess J; Norton AJ; Lister TA; Radford JA
    J Clin Oncol; 2004 Apr; 22(8):1469-79. PubMed ID: 15084620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.
    Kaminski MS; Zelenetz AD; Press OW; Saleh M; Leonard J; Fehrenbacher L; Lister TA; Stagg RJ; Tidmarsh GF; Kroll S; Wahl RL; Knox SJ; Vose JM
    J Clin Oncol; 2001 Oct; 19(19):3918-28. PubMed ID: 11579112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab.
    Kaminski MS; Radford JA; Gregory SA; Leonard JP; Knox SJ; Kroll S; Wahl RL
    J Clin Oncol; 2005 Nov; 23(31):7985-93. PubMed ID: 16204016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of patients with non-Hodgkin's lymphoma treated with Bexxar with or without external-beam radiotherapy.
    Smith K; Byer G; Morris CG; Kirwan JM; Lightsey J; Mendenhall NP; Hoppe BS; Lynch J; Olivier K
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1122-7. PubMed ID: 21570217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma.
    Leonard JP; Coleman M; Kostakoglu L; Chadburn A; Cesarman E; Furman RR; Schuster MW; Niesvizky R; Muss D; Fiore J; Kroll S; Tidmarsh G; Vallabhajosula S; Goldsmith SJ
    J Clin Oncol; 2005 Aug; 23(24):5696-704. PubMed ID: 16110029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The radioisotope contributes significantly to the activity of radioimmunotherapy.
    Davis TA; Kaminski MS; Leonard JP; Hsu FJ; Wilkinson M; Zelenetz A; Wahl RL; Kroll S; Coleman M; Goris M; Levy R; Knox SJ
    Clin Cancer Res; 2004 Dec; 10(23):7792-8. PubMed ID: 15585610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas.
    Vose JM; Wahl RL; Saleh M; Rohatiner AZ; Knox SJ; Radford JA; Zelenetz AD; Tidmarsh GF; Stagg RJ; Kaminski MS
    J Clin Oncol; 2000 Mar; 18(6):1316-23. PubMed ID: 10715303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
    J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas.
    Fisher RI; Kaminski MS; Wahl RL; Knox SJ; Zelenetz AD; Vose JM; Leonard JP; Kroll S; Goldsmith SJ; Coleman M
    J Clin Oncol; 2005 Oct; 23(30):7565-73. PubMed ID: 16186600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.
    Press OW; Unger JM; Braziel RM; Maloney DG; Miller TP; Leblanc M; Fisher RI;
    J Clin Oncol; 2006 Sep; 24(25):4143-9. PubMed ID: 16896003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma.
    Friedberg JW; Fisher RI
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):18-26. PubMed ID: 14748653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged progression-free survival and preserved quality of life in the Canadian prospective study of tositumomab and iodine(131)-tositumomab for previously treated, rituximab-exposed, indolent non-Hodgkin lymphoma.
    Olney HJ; Freeman MA; Stewart DA; Mangel JE; White DJ; Elia-Pacitti JO
    Leuk Lymphoma; 2014 Dec; 55(12):2754-60. PubMed ID: 24528219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice.
    Jacene HA; Filice R; Kasecamp W; Wahl RL
    J Nucl Med; 2007 Nov; 48(11):1767-76. PubMed ID: 17942813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin's lymphoma: initial experience.
    Bienert M; Reisinger I; Srock S; Humplik BI; Reim C; Kroessin T; Avril N; Pezzutto A; Munz DL
    Eur J Nucl Med Mol Imaging; 2005 Oct; 32(10):1225-33. PubMed ID: 15937686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 131I-tositumomab therapy as initial treatment for follicular lymphoma.
    Kaminski MS; Tuck M; Estes J; Kolstad A; Ross CW; Zasadny K; Regan D; Kison P; Fisher S; Kroll S; Wahl RL
    N Engl J Med; 2005 Feb; 352(5):441-9. PubMed ID: 15689582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 131I-Anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital.
    Turner JH; Martindale AA; Boucek J; Claringbold PG; Leahy MF
    Cancer Biother Radiopharm; 2003 Aug; 18(4):513-24. PubMed ID: 14503945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement.
    Mones JV; Coleman M; Kostakoglu L; Furman RR; Chadburn A; Shore TB; Muss D; Stewart P; Kroll S; Vallabhajosula S; Goldsmith SJ; Leonard JP
    Leuk Lymphoma; 2007 Feb; 48(2):342-8. PubMed ID: 17325895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue.
    Hohloch K; Sahlmann CO; Lakhani VJ; Wulf G; Glass B; Hasenkamp J; Meller J; Riggert J; Trümper L; Griesinger F
    Ann Hematol; 2011 Nov; 90(11):1307-15. PubMed ID: 21360108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.